Form 4: MaxCyte Director Richard Douglas Acquires Shares and Stock Options in Annual Equity Grant

Director Richard Douglas acquired 21,367 shares of common stock (restricted stock units) and stock options for 40,701 shares of MaxCyte, Inc. on June 11, 2024, as part of the company's Equity Grant Policy for non-employee directors.

Summary

• On June 11, 2024, Richard Douglas, a director of MaxCyte, Inc., acquired 21,367 shares of common stock in the form of restricted stock units (RSUs).
• Each RSU represents a contingent right to receive one share of MaxCyte's common stock.
• Douglas also acquired stock options for 40,701 shares with an exercise price of $4.68.
• The stock options expire on June 10, 2034.
• The annual grant was made pursuant to MaxCyte's Equity Grant Policy for non-employee directors.
• The shares underlying the grant vest on June 11, 2025, contingent upon Douglas's continued service as a director.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. It reflects a standard equity grant to a director, indicating confidence in the company's future. There are no red flags or negative implications.

Positives

• The equity grant aligns the director's interests with those of the shareholders.
• The vesting period encourages continued service and commitment to the company.

Industry Context

Equity grants to directors are a common practice in publicly traded companies to incentivize and retain board members, aligning their interests with those of shareholders. The size and terms of the grant are typical for non-employee directors.

Comparison to Industry Standards

• Equity grants to non-employee directors are a standard practice across the biotechnology industry.
• Companies like CRISPR Therapeutics and Editas Medicine also provide similar equity-based compensation to their directors.
• The vesting schedules and option terms are generally in line with industry norms, promoting long-term alignment with shareholder value.

Stakeholder Impact

• The equity grant aligns the director's interests with those of the shareholders, potentially leading to better governance and decision-making.
• The vesting period encourages the director's continued service, benefiting the company and its stakeholders.

Key Dates